戻る Agenda
Session 3: Performance of Clinical Trials during the Pandemic: Lessons Learned
Session Chair(s)
Nick Sykes, MS
Policy Advisor, Regulatory Strategy, EFPIA, Belgium
Rose-Marie Swallow
Senior Manager, Policy & Research, Bayer Plc., United Kingdom
The COVID pandemic had, and is continuing to have, a significant impact on our ability to run clinical trials. This panel discussion will outline some of the challenges that have been faced and some of the solutions that have been implemented to enable ongoing trials to continue and for new trials to be started. This session will also look at how some of these solutions could continue to be used in the post-pandemic setting.
Speaker(s)
Virginia Acha
AVP, Science and Regulatory Policy, Merck & Co., Inc., United Kingdom
Sponsors Perspective
Brian Barnes, MA
Director, Risk Management Strategy, Global Clinical Development Operations, BioNTech, United States
Health Inspectorate Perspective
Greet Musch, PhD
strategic adviser , FAMHP, Belgium
Competent Authorities Perspective
Ulrich Jaeger, DrMed
Professor, Medizinische Universität Wien, Austria
Investigator Side on a Current Clinical Trial